You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
泰格醫藥(03347.HK)擬成立合夥 投資生物醫藥相關行業
格隆匯 10-20 22:49

格隆匯 10 月 20日丨泰格醫藥(03347.HK)公告,於2020年10月20日,泰格股權(公司的全資附屬公司)、沃森及喬欣股權(作為有限合夥人)與懷謹投資(作為普通合夥人)訂立合夥協議,內容有關成立合夥企業。合夥協議項下所有合夥人的出資總額將為人民幣8.32億元,其中泰格股權須出資人民幣6億元。

合夥企業乃旨在投資於生物醫藥、生物技術、醫療健康及相關行業的公司。

合夥企業為根據中國法例將予成立的有限合夥企業。由於其將予成立,故公告概無呈列合夥企業的財務資料及過往業績。

懷謹投資為一家於中國成立的有限合夥企業,主要從事投資、投資管理及資產管理業務。沃森為一家於中國註冊成立的有限公司,主要從事生物製劑研發;生物項目引進、合作與開發;生物技術相關項目技術服務研發;生物製品、生物類藥品及相關材料進出口;以及技術進出口的業務。

喬欣股權為一家於中國成立的有限合夥企業,主要從事股權投資及相關諮詢服務業務。

管理人為一家於中國註冊的有限責任公司,為中國證券投資基金業協會的私募股權基金管理人。管理人主要從事基金管理業務。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account